Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug;8(15):962.
doi: 10.21037/atm.2020.03.202.

Outcomes with percutaneous mitral repair vs. optimal medical treatment for functional mitral regurgitation: systematic review

Affiliations
Review

Outcomes with percutaneous mitral repair vs. optimal medical treatment for functional mitral regurgitation: systematic review

Hector Cubero-Gallego et al. Ann Transl Med. 2020 Aug.

Abstract

Functional mitral regurgitation (MR) could be defined as a ventricular disease where mitral valve is structurally normal, left chambers are enlarged and mitral annulus is dilated with lack of coaptation of leaflets. Transcatheter mitral valve repair technique has broadened the therapeutic range in the treatment of severe MR. The aim of this study was to review outcomes of MitraClip vs. medical treatment for functional MR. We also planned to review the concept of functional MR, assessment of the degree, prognosis and therapy options. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The Medline through PubMed database was used to search. The present review included manuscripts published between January 2009 and September 2019. Two authors independently screened titles and abstracts of all publications, and performed the selection of studies and data extraction. In the case of disagreements, consensus meetings reached the final decision. Inclusion criteria were: (I) randomized controlled trials and (II) works must compare MitraClip versus optimal medical treatment. Transcatheter mitral valve repair along optimal medical treatment has been compared with optimal medical therapy in two different randomized trials. In the COAPT trial, the MitraClip group showed a significant reduction in mortality and heart failure (HF) hospitalizations. In the MITRA-FR trial, no significant differences were observed between both groups. We reviewed important aspects of functional MR and performed a comprehensive review of both trials comparing them and focusing on their differences.

Keywords: Functional mitral regurgitation; MitraClip; heart failure (HF); transcatheter mitral valve repair.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm.2020.03.202). The series “Structural Heart Disease: The Revolution” was commissioned by the editorial office without any funding or sponsorship. DHV served as the unpaid Guest Editor of the series and serves as an unpaid editorial board member of Annals of Translational Medicine from Aug 2019 to Jul 2021. The authors have no other conflicts of interest to declare.

Figures

Figure 1
Figure 1
Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) chart.
Figure 2
Figure 2
MitraClip™ (Abbott Vascular, Santa Clara, CA, USA). (A) MitraClip NTR on the left, and MitraClip XTR on the right; (B) MitraClip grasping mitral valve leaflets; (C) the clip delivery system. (Adapted with permission from Abbot. Images courtesy of Abbott. ©️ 2019 Abbott. All Rights Reserved).
Figure 3
Figure 3
Clinical case of MitraClip after failure of previous surgical repair with annuloplasty. (A) Severe mitral regurgitation; a mid (P2 towards P1) portion of the posterior mitral leaflet is flail due to ruptured chordae, with a flail gap that measures 6 mm (white arrow); (B) three-dimensional transesophageal echocardiography showed flail posterior leaflet (black arrow); (C) severe mitral regurgitation with a PISA radius of 1.7 cm; (D,E,F) transcatheter mitral valve repair (fluoroscopy); (G,H) after the MitraClip implantation, mitral regurgitation reduced to mild; (I) mitral valve area post-MitraClip of 1.8 cm2.

Similar articles

Cited by

  • Quadrangular resection versus chordal replacement for degenerative posterior mitral leaflet prolapse.
    Ma J, Liu J, Wei P, Yao X, Zhang Y, Fang L, Chen Z, Liu Y, Tan T, Wu H, Huang H, Xie B, Chen J, Zhuang J, Guo H. Ma J, et al. Ann Transl Med. 2021 Jan;9(1):60. doi: 10.21037/atm-20-7475. Ann Transl Med. 2021. PMID: 33553353 Free PMC article.
  • Transcatheter Mitral Repair for Functional Mitral Regurgitation According to Left Ventricular Function: A Real-Life Propensity-Score Matched Study.
    Pascual I, Carrasco-Chinchilla F, Benito-Gonzalez T, Li CH, Avanzas P, Nombela-Franco L, Pan M, Serrador Frutos A, Freixa X, Trillo-Nouche R, Hernández-Antolín RA, Andraka Ikazuriaga L, Cruz-Gonzalez I, López-Mínguez JR, Diez JL, Berenguer-Jofresa A, Sanchis J, Ruiz-Quevedo V, Urbano-Carrillo C, Dominguez JFO, Ortas-Nadal MR, Molina Navarro E, Carrillo X, Alonso-Briales JH, Fernández-Vázquez F, Asmarats Serra L, Hernandez-Vaquero D, Jimenez-Quevedo P, Mesa D, Rodríguez-Gabella T, Regueiro A, Martinez Monzonís A, Salido Tahoces L, Ruiz Gomez L, Trejo-Velasco B, Becerra-Muñoz VM, Garrote-Coloma C, Fernández Peregrina E, Lorca R, Agustín JA, Romero M, Amat-Santos IJ, Sabaté M, Alvarez ABC, Hernandez-Garcia JM, Gualis J, Arzamendi D, Moris C, Tirado-Conte G, Sánchez-Recalde A, Estevez-Loureiro R. Pascual I, et al. J Clin Med. 2020 Jun 9;9(6):1792. doi: 10.3390/jcm9061792. J Clin Med. 2020. PMID: 32526978 Free PMC article.
  • Asian Pacific Society of Cardiology Consensus Recommendations on the Use of MitraClip for Mitral Regurgitation.
    Yeo KK, Tan JWC, Muller DW, Walters DL, Lindenfeld J, Lee MKY, Chui ASF, Satish S, Santoso T, Kubo S, Meng JCK, Sin KY, Ewe SH, Sim D, Tay E, Meemook K, Sung SH, Nguyen QN, Pan X, Amaki M, Izumo M, Hayashida K, Kim JS, Kang DY, Stone G, Matsumoto T. Yeo KK, et al. Eur Cardiol. 2021 Jun 1;16:e25. doi: 10.15420/ecr.2021.01. eCollection 2021 Feb. Eur Cardiol. 2021. PMID: 34163538 Free PMC article. Review.

References

    1. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet 2006;368:1005-11. 10.1016/S0140-6736(06)69208-8 - DOI - PubMed
    1. Trichon BH, Felker GM, Shaw LK, et al. Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. Am J Cardiol 2003;91:538-43. 10.1016/S0002-9149(02)03301-5 - DOI - PubMed
    1. Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2017;30:303-71. 10.1016/j.echo.2017.01.007 - DOI - PubMed
    1. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017;38:2739-91. 10.1093/eurheartj/ehx391 - DOI - PubMed
    1. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017;70:252-89. 10.1016/j.jacc.2017.03.011 - DOI - PubMed